Quarterly report pursuant to Section 13 or 15(d)

Note 12 - Segment Information

v3.10.0.1
Note 12 - Segment Information
6 Months Ended
Dec. 31, 2018
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]
Note
12.
Segment Information:
 
The Company's management evaluates segment operating performance based on operating income before certain charges to cost of sales and selling, general and administrative expenses, principally associated with acquisition accounting related to inventory, stock based compensation, amortization of acquisition-related intangible assets and other acquisition-related expenses.  The Protein Sciences and Diagnostics and Genomics reportable segments both include consumables, instruments, services and royalty revenue.
 
The following is financial information relating to the Company's reportable segments (in thousands):
 
   
Quarter Ended
   
Six Months Ended
 
   
December 31,
   
December 31,
 
   
2018
   
2017
   
2018
   
2017
 
Net sales:
                               
Protein Sciences
  $
135,462
    $
117,142
    $
261,852
    $
225,255
 
Diagnostics and Genomics
   
39,263
     
37,086
     
76,010
     
73,675
 
Intersegment
   
(215
)    
(75
)
   
(382
)    
(164
)
Consolidated net sales
  $
174,510
    $
154,153
    $
337,480
    $
298,766
 
Operating income:
                               
Protein Sciences
  $
58,951
    $
50,218
    $
113,565
    $
96,427
 
Diagnostics and Genomics
   
(1,054
)    
5,888
     
1,482
     
13,167
 
Segment operating income
  $
57,897
    $
56,106
    $
115,047
    $
109,594
 
Costs recognized on sale of acquired inventory
   
(935
)    
(264
)
   
(1,869
)    
(582
)
Amortization of acquisition related intangible assets
   
(15,002
)    
(11,296
)
   
(29,278
)    
(22,675
)
Acquisition related expenses
   
(348
)    
(13,150
)
   
(2,973
)    
(22,683
)
Stock based compensation
   
(6,861
)    
(5,044
)
   
(18,426
)    
(8,839
)
Corporate general, selling, and administrative expenses
   
(1,148
)    
(2,204
)
   
(3,137
)    
(4,636
)
Consolidated operating income
  $
33,603
    $
24,148
    $
59,364
    $
50,179